Omnicomm Systems Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,160.70
522.90
835.20
1,439.30
1,176.60
1,440.50
Total Accounts Receivable
1,599.60
3,416.20
4,092.50
5,455.20
7,492.60
6,175.30
Other Current Assets
146.90
399.90
360.40
379.40
308.60
389.40
Total Current Assets
2,907.20
4,339.00
5,288.10
7,273.90
8,977.70
8,005.20
Net Property, Plant & Equipment
607.40
468.10
683.70
637.60
552.50
1,360.30
Intangible Assets
946.00
800.50
148.90
108.90
97.90
730.80
Other Assets
251.90
195.80
196.70
110.00
46.70
131.90
Total Assets
4,712.50
5,803.40
6,317.30
8,130.40
9,674.90
10,228.20
ST Debt & Current Portion LT Debt
12,682.70
13,714.50
75.00
50.00
50.00
Accounts Payable
724.40
613.60
515.80
697.10
1,303.10
Other Current Liabilities
5,645.40
8,084.00
12,274.80
15,863.70
14,086.80
Total Current Liabilities
19,052.50
22,412.00
12,865.60
16,610.70
15,439.90
Long-Term Debt
14,772.70
16,103.30
12,212.50
10,249.60
9,475.70
Provision for Risks & Charges
-
669.80
464.60
108.70
-
Other Liabilities
2,348.10
2,393.10
2,193.20
2,289.20
1,952.40
Total Liabilities
36,173.30
41,578.20
27,735.80
29,258.10
26,868.00
Common Equity (Total)
36,183.10
40,497.00
25,653.20
22,127.80
18,193.10
Total Shareholders' Equity
31,460.90
35,774.80
21,418.50
21,127.80
17,193.10
Total Equity
31,460.90
35,774.80
21,418.50
21,127.80
17,193.10
Liabilities & Shareholders' Equity
4,712.50
5,803.40
6,317.30
8,130.40
9,674.90
Preferred Stock (Carrying Value)
4,722.20
4,722.20
4,234.70
1,000.00
1,000.00

About Omnicomm Systems

View Profile
Address
2101 West Commercial Boulevard
Fort Lauderdale Florida 33309
United States
Employees -
Website http://www.omnicomm.com
Updated 07/08/2019
OmniComm Systems, Inc. engages in the provision of software solutions in the field of sciences. It supports customers through innovative technologies in management of risks, regulatory compliance, and clinical operations in the field of pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers. Its products include 21 CFR Part 11 designed to offer clinical trial sponsors the ability to conduct clinical trials under multiple platforms.